Business · 09/12/2021Updated: 10/17/2026 · 1 min read
Fresenius Kabi Deutschland GmbH Seeks Withdrawal of FDA Approval for VOLUVEN
Summary
The FDA is withdrawing approval of a new drug application for VOLUVEN, a 6% hydroxyethyl starch solution, due to Fresenius Kabi Deutschland GmbH's request, as the drug is no longer commercially available.